eczema

Saplings growing with increasing denominations of money wrapped around them
Biotech

Regeneron backs $75M series A for antibody upstart Infinimmune

The raise will support two eczema drugs that Infinimmune plans to push into the clinic next year.
Darren Incorvaia Aug 11, 2026 8:00am
Sanofi

Sanofi won't seek approval for eczema drug from Kymab buyout

Jul 24, 2026 5:13am
IPO initial public offering

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Jul 15, 2026 4:09am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

Jun 22, 2026 7:59am
Money present

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

May 27, 2026 8:57am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am